Ratings by JPMorgan (Daniel Wolle)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/13/2023 | Immunogen Inc. | IMGN | Upgrade | Overweight (Neutral) |
15.45 (31.25) |
102.27% | Details | |
| 1/23/2023 | Immunogen Inc. | IMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/17/2023 | Deciphera | DCPH | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | Deciphera | DCPH | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2022 | Immunogen Inc. | IMGN | New Coverage | Neutral (N/A) |
4.74 (15.45) |
225.95% | Details | |
| 8/2/2022 | Lava Therapeutics NV | LVTX | New Coverage | Overweight (N/A) |
2.60 (1.74) |
-33.08% | Details | |
| 8/2/2022 | Amarin Corporation | AMRN | New Coverage | Underweight (N/A) |
1.33 (14.13) |
962.41% | Details | |
| 8/2/2022 | Deciphera | DCPH | New Coverage | Neutral (N/A) |
12.69 (25.59) |
101.65% | Details |
